Letrozole as a Treatment of Endometrial Cancer

Article

Letrozole is a drug that blocks estrogen production, which causes endometrial cancer to grow in some cases. This study will examine whether the investigators may be able to predict which patients might benefit from Letrozole treatment by studying the different forms of the estrogen-receptor molecule that exist within the cancer tissues.

Study Type: Interventional

Age/Sex Requirement: 40 years+ (female)

Sponsor: University of California, Davis

Purpose: Letrozole is a drug that blocks estrogen production, which causes endometrial cancer to grow in some cases. This study will examine whether the investigators may be able to predict which patients might benefit from Letrozole treatment by studying the different forms of the estrogen-receptor molecule that exist within the cancer tissues. The study will be monitoring changes in estradiol level and apoptosis before treatment with Letrozole and at around 3 weeks following treatment.

Click here to learn more about this clinical trial.

Related Videos
Video 10 - "Future Treatment Landscape for COPD"
Video 9 - "Emerging Treatment Approaches in COPD"
A panel of 4 experts on HIV
A panel of 4 experts on HIV
Kelly Nichols, OD; Laura Periman, MD; and Mile Brujic, OD
What Makes JAK Inhibitors Safe in Dermatology
Potential JAK Inhibitor Combination Regimens in Dermatology
Therapies in Development for Hidradenitis Suppurativa
"Prednisone without Side Effects": The JAK Inhibitor Ceiling in Dermatology
© 2024 MJH Life Sciences

All rights reserved.